Journal Guide

Cancer is a complex problem. The international effort to understand and control it involves clinicians trained in many branches of medicine and scientists from most biological disciplines, chemistry, pharmaceutical and physical sciences. British Journal of Cancer (BJC) exists to serve the needs of this diverse community, providing a forum for prompt communication of original and innovative research findings that have relevance to understanding the etiology of cancer and to improving the treatment and survival of patients. BJC works with a distinguished team of international experts to ensure the highest standards of selection and review. All relevant papers are carefully considered. Once accepted, papers are published rapidly in print and online.Full research papers and short communications are published under five broad headings: * clinical studies * translational therapeutics * molecular diagnostics * genetics and genomics * epidemiologyBJC regularly invites minireviews on topics of current interest from international authorities. Some longer reviews, and book reviews are published, usually by editor's invitation. Editorials and letters to the editor on matters arising from published papers are also published at the editor's discretion.BJC is owned by Cancer Research UK, the world's leading independent charity dedicated to cancer research. Cancer Research UK carries out scientific research to find news ways of preventing, diagnosing and treating cancer; ensuring findings are used to benefit the lives of cancer patients.BJC reflects this purpose. It was founded more than sixty years ago and, from the start, its far-sighted mission was to encourage communication of the very best cancer research from laboratories and clinics in all countries. Broad coverage, its editorial independence and consistent high standards have made British Journal of Cancer one of the world's premier general cancer journals.

From Biology to Clinical practice : a modern approach of oncologyWhile giving space to review articles and paying more attention to biological aspects, the Bulletin du Cancer maintains a highly scientific clinical and therapeutic approach.The Bulletin du Cancer is one of the best scientific publications in the French language in the realm of cancerology. It is listed in the leading international databases.The Bulletin du Cancer is the official organ of the French Cancer Society.The online version of Bulletin du Cancer is available. All articles published since 1997 can now be accessed online. Recent articles are available by pay per view or by subscription while older ones have free access.

The CANCER site is a full-text, electronic implementation of CANCER, an Interdisciplinary International Journal of the American Cancer Society, and CANCER CYTOPATHOLOGY, a Journal of the American Cancer Society. The print and online versions of the journal are published by John Wiley & Sons, Inc.

Cancer, the second leading cause of death, is a heterogenous group of over 100 diseases. Cancer is characterized by disordered and deregulated cellular and stromal proliferation accompanied by reduced cell death with the ability to survive under stresses of nutrient and growth factor deprivation, hypoxia, and loss of cell-to-cell contacts. At the molecular level, cancer is a genetic disease that develops due to the accumulation of mutations over time in somatic cells. The phenotype includes genomic instability and chromosomal aneuploidy that allows for acceleration of genetic change. Malignant transformation and tumor progression of any cell requires immortalization, loss of checkpoint control, deregulation of growth, and survival. A tremendous amount has been learned about the numerous cellular and molecular genetic changes and the host-tumor interactions that accompany tumor development and progression. It is the goal of the field of Molecular Oncology to use this knowledge to understand cancer pathogenesis and drug action, as well as to develop more effective diagnostic and therapeutic strategies for cancer. This includes preventative strategies as well as approaches to treat metastases. With the availability of the human genome sequence and genomic and proteomic approaches, a wealth of tools and resources are generating even more information. The challenge will be to make biological sense out of the information, to develop appropriate models and hypotheses and to translate information for the clinicians and the benefit of their patients. Cancer Biology & Therapy aims to publish original research on the molecular basis of cancer, including articles with translational relevance to diagnosis or therapy. We will include timely reviews covering the broad scope of the journal. The journal will also publish op-ed pieces and meeting reports of interest. The goal is to foster communication and rapid exchange of information through timely publication of important results using traditional as well as electronic formats. The journal and the outstanding Editorial Board will strive to maintain the highest standards for excellence in all activities to generate a valuable resource.

Concentrating on molecular biomarkers in cancer research, Cancer Biomarkers publishes original research findings (and reviews solicited by the editor) on the subject of the identification of markers associated with the disease processes whether or not they are an integral part of the pathological lesion. The disease markers may include, but are not limited to, genomic, epigenomic, proteomics, cellular and morphologic, and genetic factors predisposing to the disease or indicating the occurrence of the disease. Manuscripts on these factors or biomarkers, either in altered forms, abnormal concentrations or with abnormal tissue distribution leading to disease causation will be accepted.

Cancer Biotherapy and Radiopharmaceuticals is a peer-reviewed journal covering cutting-edge biotherapy and innovative investigations of methods to improve cancer therapy. Includes more selective delivery of drugs, biologicals, radiopharmaceuticals, and other agents, and advances in delivery instrumentation and technology, with the aim of increasing efficacy of therapy, decreasing toxicity, and/or improving convenience of therapy.Topics include:• Pre-targeted cancer therapy• Clinical trials in cancer research• Antibody therapy and imaging• Tumor cell vaccines• Radioimmunotherapy• T-cell therapy• Molecular targeted therapy and imaging• Drug resistance.

Cancer Causes & Control is an international refereed journal that both reports and stimulates new avenues of investigation into the causes, control, and subsequent prevention of cancer. Its multidisciplinary and multinational approach draws together information published in a diverse range of journals. Coverage extends to variation in cancer distribution within and between populations; factors associated with cancer risk; preventive and therapeutic interventions on a population scale; economic, demographic, and health-policy implications of cancer; and related methodological issues.Cancer Causes & Control publishes original and review articles, hypotheses, comments, opinions, and letters which have direct relevance to researchers and practitioners working in epidemiology, medical statistics, cancer biology, health education, medical economics and related fields. The journal also provides significant information for government agencies concerned with cancer research, control and policy.

Cancer Cell publishes reports of novel results in any area of cancer research, from molecular and cellular biology to clinical oncology. The work should be not only of exceptional significance within its field but also of interest to researchers outside the immediate area. In addition, Cancer Cell findings in cancer research, diagnosis and treatment. The goal ofCancer Cell is to promote the exchange of ideas and concepts across the entire cancer community, cultivating new areas of basic research and clinical investigation.Cancer Cell will consider papers for publication in any aspect of cancer biology and clinical research, including (but not limited to): Genetics, epigenetics, genomic instability • Cell signaling and communication • Cell cycle, DNA repair • Diagnostics (molecular profiling, pharmacogenomics) • Telomerase and transformation • Apoptosis • Angiogenesis, metastasis • Animal models • Cancer therapy (rational drug design, small molecule therapeutics) • Epidemiology and prevention.Visit the Cancer Cell website to find out more - http://www.cancercell.org .

Cancer Cell International is ready to receive manuscripts on all aspects of cancer cell biology.

Cancer Chemotherapy and Pharmacology addresses a wide range of pharmacologic and oncologic concerns on both experimental and clinical levels. The primary focus of this rapid publication medium is on new anticancer agents, their experimental screening, preclinical toxicology and pharmacology, single and combined drug administration modalities, and clinical phase I, II and III trials. The journal publishes results recorded in the following areas: clinical toxicology, pharmacokinetics, pharmacodynamics, drug interactions, and indications for chemotherapy in cancer treatment strategy. Cancer Chemotherapy and Pharmacology is essential reading for pharmacologists and oncologists.

The CANCER site is a full-text, electronic implementation of CANCER , an Interdisciplinary International Journal of the American Cancer Society, and CANCER CYTOPATHOLOGY. The print and online versions of the journal are published by John Wiley & Sons, Inc. The site offers access to current issues since 1997 of CANCER including CANCER CYTOPATHOLOGY in HTML format, with embedded links to figures and tables, as well as CrossRef™ links, which take users to cited articles that may have been published by a different publisher. There is unrestricted access to tables of contents, abstracts, and general information about CANCER and CANCER CYTOPATHOLOGY, as well as to other Wiley journals. The full-text is available to all subscribers following registration . The CANCER CYTOPATHOLOGY section targets these areas:

Cancer Epidemiology's 2012 Impact Factor is 2.232 (© Thomson Reuters Journal Citation Reports 2013).Cancer Epidemiology: the international journal for cancer epidemiology, detection and prevention is dedicated to increasing understanding about cancer causes, prevention and control. The scope of the journal embraces all aspects of cancer epidemiology including:• Descriptive epidemiology and statistics• Studies of risk factors for disease initiation, development and prognosis• Screening, early detection and accurate diagnosis• Prevention and evaluation of interventions• Methodological issues and theoryThe journal publishes original research articles (full length and short reports), systematic reviews and meta-analyses, editorials, commentaries and letters to the editor commenting on previously published research.Cancer Epidemiology (Cancer Epidemiol.) is indexed and abstracted in: MEDLINE/PubMed, Current Contents/Clinical Medicine, the Science Citation Index Expanded, and Thomson Reuters Journal Citation Reports (Science Edition).

Cancer Gene Therapy publishes the results of laboratory investigations, preclinical studies, and clinical trials in the field of gene transfer/gene therapy and cellular therapies as applied to cancer research. Types of articles published include original research articles; case reports; preliminary communications; review articles in the main fields of drug resistance/sensitivity, gene therapy, cellular therapy, tumor suppressor and anti-oncogene therapy, cytokine/tumor immunotherapy, etc.; industry perspectives; and letters to the editor.

The aim of Cancer Genetics is to publish high quality scientific papers on the cellular, genetic and molecular aspects of cancer, including cancer predisposition and clinical diagnostic applications. Specific areas of interest include descriptions of new chromosomal, molecular or epigenetic alterations in benign and malignant diseases; novel laboratory approaches for identification and characterization of chromosomal rearrangements or genomic alterations in cancer cells; correlation of genetic changes with pathology and clinical presentation; and the molecular genetics of cancer predisposition. To reach a basic science and clinical multidisciplinary audience, we welcome original full-length articles, reviews, meeting summaries, brief reports, and letters to the editor.Benefits to authorsWe also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services.Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our support pages: http://support.elsevier.com

Cancer Genomics & Proteomics (CGP) is an international journal designed to publish rapidly high quality articles and reviews on the application of genomic and proteomic technology to basic, experimental and clinical cancer research. In this site you may find information concerning the editorial board, editorial policy, issue contents, subscriptions, submission of manuscripts and advertising. The first issue of CGP circulated in January 2004.Cancer Genomics & Proteomics is published bimonthly by the International Institute of Anticancer Research.Cancer Genomics & Proteomics supports (a) the aims and the research projects of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.Cancer Genomics & Proteomics is published bimonthly. Each annual volume contains six issues and index.Articles in Cancer Genomics & Proteomics are regularly indexed in the following bibliographic services: PUBMED - MEDLINE, CAS (Chemical Abstracts Service), BIOLOGICAL ABSTRACTS, EMBASE and BIOBASE (Elsevier Bibliographic Databases), BIOSIS PREVIEWS, LEEDS MEDICAL INFORMATION CSA ILLUMINA (Cambridge Scientific Abstracts, including: Oncogenes & Growth Factors, Genetics, Medical & Pharmaceutical Biotechnology, Bioengineering), All-Russian Institute of Scientific and Technical Information - VINITI Abstracts Journal, Sociedad Iberoamericana de Information Cientifica (SIIC) Data Bases.

http://cancerimmunolres.aacrjournals.org/site/misc/about.xhtml

Since its inception in 1976, Cancer Immunology, Immunotherapy (CII) has reported significant advances in the field of tumor immunology.  The journal serves as a forum for new concepts and advances in basic, translational, and clinical cancer immunology and immunotherapy. CII is keen to publish broad-ranging ideas and reviews, results which extend or challenge established paradigms, as well as negative studies which fail to reproduce experiments that support current paradigms, and papers that do succeed in reproducing others’ results in different contexts.In addition to publishing original research articles and reviews, CII also offers the following unique publication formats:·         “Focussed Research Reviews,” published together with a conference meeting report, which provide individual speakers with the opportunity to expand on the ideas and concepts they presented at the conference.·         “Symposia-in-Writing,” which are virtual workshops consisting of a series of complime